Investor Presentaiton
SAR-Bombesin clinical development
ASCO 2022 Annual Meeting Abstract: 3092 | Poster: 82
C-BOBCAT: Results to be published at the
2022 ASCO Annual Meeting in June
First-in-human pilot trial assessment of the
diagnostic value of 64CU SAR-Bombesin PET/CT
imaging for staging of hormone positive breast
cancer patients with metastatic disease in
comparison with standard of care imaging (CT,
bone scan and 18F FDG PET/CT)
Study Sponsor: St Vincent's Hospital, Sydney
Pl: Prof. Louise Emmett
•
•
Future milestones
64CU SAR-Bombesin diagnostic IND expected 1H 2022
Initial US diagnostic trial in PSMA negative prostate cancer patients to
commence 2H 2022
67CU SAR-Bombesin therapy IND to be lodged 2H 2022
C-BOBCAT: One hour post 64CU-SAR-Bombesin administration in a breast cancer patient
18F FDG
64CU SAR-Bombesin
A
B
•
Data from the C-BOBCAT trial shows that 64Cu
SAR-Bombesin is highly avid with a high tumour
volume compared to 18F FDG in some patients
Results indicate 64CU SAR-Bombesin may have a
role in imaging patients with hormone positive
breast cancer, particularly lobular subtype
CLARITY
2014 MILE
ST VINCENTS
HOSPITAL
SYDNEY
PET/CT
PET/CT
CT
CT
PET
PET
19View entire presentation